Tim Overend

1.2k total citations
32 papers, 975 citations indexed

About

Tim Overend is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Tim Overend has authored 32 papers receiving a total of 975 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 17 papers in Physiology and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Tim Overend's work include Chronic Obstructive Pulmonary Disease (COPD) Research (24 papers), Asthma and respiratory diseases (17 papers) and Inhalation and Respiratory Drug Delivery (15 papers). Tim Overend is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (24 papers), Asthma and respiratory diseases (17 papers) and Inhalation and Respiratory Drug Delivery (15 papers). Tim Overend collaborates with scholars based in United Kingdom, United States and Canada. Tim Overend's co-authors include Donald Banerji, Yimeng Lu, Michael Dolker, J.A. van Noord, Anthony D’Urzo, Vijay Alagappan, Edward Kerwin, Jacques Hébert, Nicola Gallagher and Gary T. Ferguson and has published in prestigious journals such as European Respiratory Journal, Thorax and Respiratory Medicine.

In The Last Decade

Tim Overend

32 papers receiving 924 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim Overend United Kingdom 16 881 725 44 36 33 32 975
Charles W. Serby United States 9 1.3k 1.5× 1.0k 1.4× 2 0.0× 31 0.9× 34 1.0× 10 1.4k
DP Tashkin United States 4 213 0.2× 263 0.4× 6 0.1× 13 0.4× 7 0.2× 11 393
Vittorio Cardaci Italy 12 324 0.4× 121 0.2× 8 0.2× 40 1.1× 14 0.4× 28 464
Jacques P.H.M. Creemers Netherlands 12 476 0.5× 444 0.6× 7 0.2× 11 0.3× 15 0.5× 18 635
Lili Guan China 13 239 0.3× 46 0.1× 58 1.3× 26 0.7× 16 0.5× 36 416
L. Korducki United States 2 846 1.0× 622 0.9× 1 0.0× 19 0.5× 29 0.9× 3 891
Sears Mr New Zealand 8 166 0.2× 182 0.3× 13 0.3× 12 0.3× 14 0.4× 15 301
Edward G. Nassif United States 7 238 0.3× 251 0.3× 21 0.5× 7 0.2× 7 0.2× 8 423
Roopa Trivedi United States 12 781 0.9× 588 0.8× 2 0.0× 50 1.4× 8 0.2× 30 901
S.G.M. Cloosterman Netherlands 13 286 0.3× 359 0.5× 5 0.1× 16 0.4× 7 0.2× 18 417

Countries citing papers authored by Tim Overend

Since Specialization
Citations

This map shows the geographic impact of Tim Overend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim Overend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim Overend more than expected).

Fields of papers citing papers by Tim Overend

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim Overend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim Overend. The network helps show where Tim Overend may publish in the future.

Co-authorship network of co-authors of Tim Overend

This figure shows the co-authorship network connecting the top 25 collaborators of Tim Overend. A scholar is included among the top collaborators of Tim Overend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim Overend. Tim Overend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rohde, Gernot, Stephan Stenglein, Hans Prozesky, et al.. (2023). Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial. EClinicalMedicine. 65. 102237–102237. 11 indexed citations
2.
Papi, Alberto, et al.. (2017). Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. International Journal of COPD. Volume 12. 1961–1971. 20 indexed citations
3.
Chapman, Kenneth R., Kai Michael Beeh, Jutta Beier, et al.. (2014). A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulmonary Medicine. 14(1). 4–4. 66 indexed citations
4.
Overend, Tim, Didier Renard, M.R.J. Gibbs, et al.. (2012). A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulmonary Medicine. 12(1). 74–74. 30 indexed citations
5.
Kerwin, Edward, Jacques Hébert, Nicola Gallagher, et al.. (2012). Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. European Respiratory Journal. 40(5). 1106–1114. 180 indexed citations
6.
Kerwin, Edward, Andrew Pedinoff, Thomas B. Casale, et al.. (2012). NVA237 Once Daily Reduces COPD Exacerbations With Similar Rates To Tiotropium: The GLOW2 Trial. A2255–A2255. 2 indexed citations
7.
8.
D’Urzo, Anthony, et al.. (2011). NVA237 once daily reduces the percentage of patients with exacerbations of COPD and associated hospitalizations: The GLOW1 trial. European Respiratory Journal. 38(Suppl 55). 3427–3427. 1 indexed citations
9.
D’Urzo, Anthony, Gary T. Ferguson, Motokazu Kato, et al.. (2011). NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial. European Respiratory Journal. 38(Suppl 55). p866–p866. 2 indexed citations
10.
D’Urzo, Anthony, Gary T. Ferguson, J.A. van Noord, et al.. (2011). Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respiratory Research. 12(1). 156–156. 152 indexed citations
11.
Verkindre, C., et al.. (2010). Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respiratory Medicine. 104(10). 1482–1489. 59 indexed citations
12.
Vogelmeier, Claus, C. Verkindre, D. Cheung, et al.. (2010). Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Pulmonary Pharmacology & Therapeutics. 23(5). 438–444. 48 indexed citations
13.
Noord, J.A. van, Roland Buhl, Craig LaForce, et al.. (2010). QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 65(12). 1086–1091. 90 indexed citations
14.
Fabbri, Leonardo M., et al.. (2010). Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients. COPD Journal of Chronic Obstructive Pulmonary Disease. 7(6). 418–427. 51 indexed citations
15.
Neder, J. Alberto, Jonathan Fuld, Tim Overend, et al.. (2007). Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respiratory Medicine. 101(10). 2056–2064. 40 indexed citations
16.
Bouros, Demosthenes, John Kottakis, Vincent Gros, et al.. (2004). Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV1 reversibility. Current Medical Research and Opinion. 20(5). 581–586. 26 indexed citations
17.
Benhamou, D., A. Cuvelier, Vincent Gros, et al.. (2004). FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer® in chronic obstructive pulmonary disease. International Journal of Clinical Practice. 58(5). 457–464. 6 indexed citations
18.
Kottakis, John, Giovanni Della Cioppa, Jacques P.H.M. Creemers, et al.. (2002). Faster Onset of Bronchodilation with Formoterol than with Salmeterol in Patients with Stable, Moderate‐Severe Copd: Results of a Randomized, Double‐Blind Clinical Study. Canadian Respiratory Journal. 9(2). 107–115. 42 indexed citations
19.
Lindsay, William R., Anne H. W. Smith, Jacqueline Law, et al.. (2002). A Treatment Service for Sex Offenders and Abusers with Intellectual Disability: Characteristics of Referrals and Evaluation. Journal of Applied Research in Intellectual Disabilities. 15(2). 166–174. 48 indexed citations
20.
Eliraz, A, Alicia Ramírez‐Rivera, G. Rapatz, et al.. (2001). SIMILAR EFFICACY FOLLOWING FOUR WEEKS TREATMENT OF ASTHMATICS WITH FORMOTEROL 12 μG B.D. DELIVERED BY TWO DIFFERENT DRY POWDER INHALERS: DIFFERENCES IN INHALER HANDLING. International Journal of Clinical Practice. 55(3). 164–170. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Charles W. Serby Breakdown of academic impact, for papers by DP Tashkin Breakdown of academic impact, for papers by Vittorio Cardaci Breakdown of academic impact, for papers by Jacques P.H.M. Creemers Breakdown of academic impact, for papers by Lili Guan Breakdown of academic impact, for papers by L. Korducki Breakdown of academic impact, for papers by Sears Mr Breakdown of academic impact, for papers by Edward G. Nassif Breakdown of academic impact, for papers by Roopa Trivedi Breakdown of academic impact, for papers by S.G.M. Cloosterman
Rankless by CCL
2026